Joachim Kreuzburg - Sartorius Aktiengesellscha Chairman
| SARTF Stock | USD 182.98 9.77 5.07% |
Chairman
Dr. Joachim Kreuzburg was Chairman of the Executive Board, Chief Executive Officer of Sartorius Aktiengesellschaft since November 11, 2015. He was Chairman of the Executive Board, Chief Executive Officer, Executive for Labor Relations of Sartorius AG from July 24, 2009. He was Chairman of the Management Board, Chief Executive Officer from November 11, 2005. He is responsible for Corporationrationrate Strategy, Legal, Compliance. Human Resources, Corporationrationrate Research and Communications. He joined the Management Board in November 2002. Before that, he was Vice President of Treasury Investor Relations. From May 1, 2003 till November 10, 2005, he has served as Spokesman of the Management Board. He serves as Chairman of the Board of Directors and Chief Executive Officer of Sartorius Stedim Biotech S.A. He is on the Board of Directors of various companies within the Sartorius Group. His other appointments include being Member of the Advisory Board of Commerzbank AG, Norddeutsche Landesbank, among others. He studied Mechanical Engineering at the Gottfried Wilhelm Leibniz Universitaet Hannover, Germany. He also holds a doctorate in Economics. since 2015.
| Age | 58 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Phone | 49 551 308 0 |
| Web | https://www.sartorius.com |
Sartorius Aktiengesellscha Management Efficiency
The company has return on total asset (ROA) of 0.106 % which means that it generated a profit of $0.106 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3386 %, meaning that it generated $0.3386 on every $100 dollars invested by stockholders. Sartorius Aktiengesellscha's management efficiency ratios could be used to measure how well Sartorius Aktiengesellscha manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 5 records | CHAIRMAN Age | ||
| Vivek Jain | ICU Medical | 52 | |
| Peter Farrell | ResMed Inc | 78 | |
| Caren Mason | STAAR Surgical | 70 | |
| Fred Lampropoulos | Merit Medical Systems | 74 | |
| Patrick Zenner | West Pharmaceutical Services | 73 | |
Management Performance
| Return On Equity | 0.34 | |||
| Return On Asset | 0.11 |
Sartorius Aktiengesellscha Leadership Team
Elected by the shareholders, the Sartorius Aktiengesellscha's board of directors comprises two types of representatives: Sartorius Aktiengesellscha inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sartorius. The board's role is to monitor Sartorius Aktiengesellscha's management team and ensure that shareholders' interests are well served. Sartorius Aktiengesellscha's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sartorius Aktiengesellscha's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rene Faber, Member of the Executive Board, Head of the Bioprocess Solutions Division | ||
| Petra Kirchhoff, Member of the Supervisory Board, Vice President of Corporate Communications & Investor Relations | ||
| Rashid Maqbool, Head USA | ||
| Manfred Werner, Sr Auditing | ||
| John MacKay, Member of the Executive Board, Head of the Lab Products & Services Division | ||
| Patricia Spannagel, Head Goettingen | ||
| Mei Wang, Head China | ||
| Joachim Kreuzburg, Chairman of the Executive Board, CEO, Executive for Labor Relations | ||
| Rainer Lehmann, CFO, Member of the Executive Board | ||
| Manohar Kuppusami, Head India |
Sartorius Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sartorius Aktiengesellscha a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.34 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 0.27 % | |||
| Current Valuation | 27.76 B | |||
| Shares Outstanding | 34.23 M | |||
| Shares Owned By Insiders | 84.78 % | |||
| Shares Owned By Institutions | 3.73 % | |||
| Price To Earning | 58.19 X | |||
| Price To Book | 11.12 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Sartorius Pink Sheet
Sartorius Aktiengesellscha financial ratios help investors to determine whether Sartorius Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sartorius with respect to the benefits of owning Sartorius Aktiengesellscha security.